BRPI0408097A - composição de insulina oral e processos para a produção e para o uso da mesma - Google Patents

composição de insulina oral e processos para a produção e para o uso da mesma

Info

Publication number
BRPI0408097A
BRPI0408097A BRPI0408097-1A BRPI0408097A BRPI0408097A BR PI0408097 A BRPI0408097 A BR PI0408097A BR PI0408097 A BRPI0408097 A BR PI0408097A BR PI0408097 A BRPI0408097 A BR PI0408097A
Authority
BR
Brazil
Prior art keywords
composition
processes
production
insulin
mammal
Prior art date
Application number
BRPI0408097-1A
Other languages
English (en)
Inventor
Wladimir Sabetsky
Original Assignee
Technology Dev Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technology Dev Company Ltd filed Critical Technology Dev Company Ltd
Publication of BRPI0408097A publication Critical patent/BRPI0408097A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

"COMPOSIçãO DE INSULINA ORAL E PROCESSOS PARA A PRODUçãO E PARA O USO DA MESMA". A presente invenção refere-se a um processo de diminuição da glicose no sangue em um mamífero que inclui a administração oral de uma quantidade terapeuticamente eficaz de micropartículas de dextrana cristalizadas e insulina ao mamífero para diminuir a glicose no sangue do mamífero. A composição pode ser uma composição de uma fase ou multifásica estruturada para a liberação controlada de insulina.
BRPI0408097-1A 2003-03-04 2004-03-04 composição de insulina oral e processos para a produção e para o uso da mesma BRPI0408097A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45124503P 2003-03-04 2003-03-04
US46760103P 2003-05-05 2003-05-05
US46901703P 2003-05-09 2003-05-09
US49509703P 2003-08-15 2003-08-15
IB2004009333 2004-03-04

Publications (1)

Publication Number Publication Date
BRPI0408097A true BRPI0408097A (pt) 2006-02-14

Family

ID=32831112

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0408100-5A BRPI0408100A (pt) 2003-03-04 2004-03-04 composição de insulina injetável de atuação longa e processos de produção e de utilização da mesma
BRPI0408105-6A BRPI0408105A (pt) 2003-03-04 2004-03-04 sistema de distribuição para droga e terapia celular
BRPI0408097-1A BRPI0408097A (pt) 2003-03-04 2004-03-04 composição de insulina oral e processos para a produção e para o uso da mesma

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BRPI0408100-5A BRPI0408100A (pt) 2003-03-04 2004-03-04 composição de insulina injetável de atuação longa e processos de produção e de utilização da mesma
BRPI0408105-6A BRPI0408105A (pt) 2003-03-04 2004-03-04 sistema de distribuição para droga e terapia celular

Country Status (17)

Country Link
US (5) US20110097385A1 (pt)
EP (3) EP1454630B1 (pt)
JP (3) JP2006519252A (pt)
KR (3) KR20060015472A (pt)
AR (1) AR046485A1 (pt)
AT (1) ATE485051T1 (pt)
AU (3) AU2004216911A1 (pt)
BR (3) BRPI0408100A (pt)
CA (3) CA2518143A1 (pt)
DE (1) DE602004029630D1 (pt)
EA (3) EA200501421A1 (pt)
EC (3) ECSP056078A (pt)
MX (1) MXPA05009493A (pt)
NO (3) NO20054534L (pt)
PT (1) PT1454630E (pt)
TW (1) TW200529869A (pt)
WO (3) WO2004078196A1 (pt)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166132A1 (en) * 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
CA2479751C (en) 2002-03-20 2008-06-03 Trent Poole Inhalation apparatus
JP2006519252A (ja) * 2003-03-04 2006-08-24 ザ・テクノロジー・デヴェロップメント・カンパニー・リミテッド 薬物送達系および細胞療法
BRPI0413276B8 (pt) * 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
TW200603843A (en) * 2004-04-20 2006-02-01 Technology Dev Company Ltd Tissue enhancement implant and method
US7709639B2 (en) 2004-08-20 2010-05-04 Mannkind Corporation Catalysis of diketopiperazine synthesis
KR20150039211A (ko) 2004-08-23 2015-04-09 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
FR2880272A1 (fr) * 2005-01-04 2006-07-07 Jean Marc Ruiz Preparation contenant des microparticules d'un sel de polymere insoluble portant un principe actif, ainsi que son procede de fabrication
WO2007025441A1 (en) * 2005-08-29 2007-03-08 Tuo Jin Polysaccharide microparticles containing biological agents: there preparation and applications
AU2006290227B2 (en) * 2005-09-14 2012-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
WO2007074133A2 (en) * 2005-12-28 2007-07-05 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
SE529040C2 (sv) * 2006-01-18 2007-04-17 Bows Pharmaceuticals Ag Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin
MX2008010721A (es) 2006-02-22 2008-09-01 Mannkind Corp Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
JP2010505616A (ja) * 2006-10-06 2010-02-25 プレジデント アンド フェロウズ オブ ハーバード カレッジ 材料の化学的に指向された静電的自己集成体
CN101677947B (zh) 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
EP2025334A1 (en) * 2007-07-25 2009-02-18 OctoPlus Sciences B.V. Sustained release drug delivery system for repeated administration
CN104689432B (zh) 2008-06-13 2018-07-06 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
BRPI0914308B8 (pt) 2008-06-20 2021-06-22 Mannkind Corp sistema de inalação
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
FR2940802A1 (fr) * 2008-10-10 2010-07-09 Adocia Complexe entre l'insuline humaine et un polymere amphiphile et utilisation de ce complexe pour la preparation d'une formulation d'insuline humaine rapide.
DK3228320T3 (da) 2008-10-17 2020-03-09 Sanofi Aventis Deutschland Kombination af et insulin og en glp-1-agonist
US9603904B2 (en) * 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
JP5667095B2 (ja) 2009-03-11 2015-02-12 マンカインド コーポレイション 吸入器の抵抗を測定するための装置、システムおよび方法
FR2943538B1 (fr) * 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
US8734845B2 (en) 2009-06-12 2014-05-27 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9068182B2 (en) * 2009-07-28 2015-06-30 Corning Incorporated Synthetic polysaccharide microcarriers for culturing cells
HUP0900482A2 (en) 2009-08-03 2011-03-28 Cera Med Kft Pharmaceutical formulation for oral administration
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
WO2011058082A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
NZ599848A (en) 2009-11-13 2013-08-30 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
JP6385673B2 (ja) 2010-06-21 2018-09-05 マンカインド コーポレイション 乾燥粉末薬物送達システム
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US10143754B2 (en) * 2011-08-07 2018-12-04 Transgene Biotek Limited Method for peroral delivery of insulin and its analogues for therapeutic usage
CN103917241A (zh) 2011-08-29 2014-07-09 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP6018640B2 (ja) 2011-10-24 2016-11-02 マンカインド コーポレイション 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
DK2872205T3 (en) 2012-07-12 2017-02-27 Mannkind Corp DRY POWDER FORMAL ADMINISTRATION SYSTEM
US9157939B2 (en) * 2012-08-09 2015-10-13 Infineon Technologies Ag System and device for determining electric voltages
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
CN107952065A (zh) 2012-11-13 2018-04-24 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
CN105142661B (zh) 2013-04-03 2019-08-16 赛诺菲 通过长效胰岛素制剂治疗糖尿病
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
JP6200698B2 (ja) * 2013-06-18 2017-09-20 ニュートリー株式会社 嚥下造影検査食
MX2020009878A (es) 2013-07-18 2022-07-27 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos.
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
RU2014120626A (ru) * 2014-05-22 2015-11-27 Владимир Андреевич Сабецкий Инсулинсодержащий препарат пролонгированного действия
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CN105617362B (zh) * 2014-10-27 2021-05-11 中国医学科学院药物研究所 一种新型的胰岛素－磷脂－壳聚糖自组装微粒载体及其制剂
CA2970200A1 (en) 2014-12-12 2016-06-16 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
WO2017141262A1 (en) 2016-02-19 2017-08-24 Indian Institute Of Technology, Bombay Orally administrable pharmaceutical preparation containing protein
RU2647466C1 (ru) * 2016-12-01 2018-03-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный университет" (СПбГУ) Способ получения нативного белка пролонгирующего действия в составе полимерных наносфер и резорбируемых микросфер для доставки
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR20200056359A (ko) 2020-04-29 2020-05-22 김용원 퀵보드 등 승용기구바퀴(회전자)에 설치되는 바퀴덮개(고정자)에 설치하는 발전기
KR20200056360A (ko) 2020-04-29 2020-05-22 김용원 자전거바퀴(회전자)와 바퀴덮개(고정자)에 설치하는 발전기
KR20200056361A (ko) 2020-05-04 2020-05-22 김용원 발판보드에 설치하는 발전기
KR20200060307A (ko) 2020-05-06 2020-05-29 김용원 자전거와 리어 캐리어에 설치하는 발전장치들
KR20200060308A (ko) 2020-05-07 2020-05-29 김용원 수상보드에 설치하는 발전기
KR20200060309A (ko) 2020-05-08 2020-05-29 김용원 헬스차량에 설치하는 발전기
KR20200061324A (ko) 2020-05-11 2020-06-02 김용원 보트에 설치하는 발전기
KR20200062092A (ko) 2020-05-11 2020-06-03 김용원 수차와 공기 컴프레서를 이용한 공기 터빈구조 발전기와 바퀴구조 발전기를 합한 발전기
KR20200068614A (ko) 2020-05-26 2020-06-15 김용원 펠티어소자를 이용한 공기, 물 컨디션너 조절장치 내에 설치한 발전기
KR20200083393A (ko) 2020-06-16 2020-07-08 김용원 "공기 터빈구조 발전기"와 "바퀴구조를 합한 발전기"를 "발열소자를 이용한 발전기"와 적용 양방향 모터(양방향 프로펠러)를 양방향공기추진기(Propullor)와 결합 장착한 드론
KR20200088241A (ko) 2020-06-30 2020-07-22 김용원 역방향 모터(양방향 프로펠러)의 추진에 맞는 관성을 이기는 팬이 없는 양방향공기추진기(Propullor)를 장착한 드론
KR20200108392A (ko) 2020-08-31 2020-09-18 김용원 전동 오토바이 모터의 정격에 맞는 오토바이바퀴에 회전자와 물받이 고정자 발전기를 설치한 오토바이에 모터가 장착된 항공기 공기추진기(Propulsor)와 장착한 드론의 프로퓰러(Propullor)를 장착하는 제조기술)
KR20210018367A (ko) 2021-01-26 2021-02-17 김용원 전동 오토바이에 설치한 모터가 장착된 항공기 공기추진기와 장착한 프로퓰러(Propullor)로 구성한 오토에어크라프트(Autoaircraft)
KR20210029730A (ko) 2021-02-22 2021-03-16 김용원 산사태에 대비, 대응하는 에어 레이어들 블록들이 형성된 거대장비들(에어 레이어들 블록들)
KR20210040852A (ko) 2021-03-24 2021-04-14 김용원 전동에어버스
KR20210043513A (ko) 2021-03-26 2021-04-21 김용원 전동에어버스에 설치하는 연기(분연), 재 포집장치
KR20210045369A (ko) 2021-03-31 2021-04-26 김용원 전기 에어 카
KR20210049046A (ko) 2021-04-13 2021-05-04 김용원 전기에어버스를 강풍, 태풍에 구조하는 보조날개와 보조출입문 장치
KR20210055643A (ko) 2021-04-27 2021-05-17 김용원 모터가 장착된 회전축에 다량의 회전자바퀴와 다량의 고정자바퀴발전기를 설치한 전동보드
KR20210072739A (ko) 2021-05-27 2021-06-17 김용원 의료용 전동보드
KR20210080293A (ko) 2021-06-11 2021-06-30 김용원 바퀴 사이 발전기 케이스
CN115702880B (zh) * 2021-08-12 2023-11-03 山东新时代药业有限公司 一种重组甘精胰岛素注射液及其制备工艺
KR20220016234A (ko) 2022-01-14 2022-02-08 김용원 공기추진기(공기펌프와 공기터빈)를 장착한 3륜 자전거
KR20220038026A (ko) 2022-02-24 2022-03-25 김용원 4합 공기터빈 : 공기터빈 축에 1. 인너 팬들의 인너 실린더와 2. 아웃터 팬들의 아웃터 실린더와 3. 양쪽 1. 인너 실린더들과 2. 아웃터 실린더들의 사이에 아웃터 팬들에 덕트팬들과 덕트흡입구와 4 1. 인너 실린더들과 2. 아웃터 실린더들의 사이에 아웃터 팬들의 3. 덕트팬들에 블레이드와 블레이드 외부 형틀
KR20220056159A (ko) 2022-04-04 2022-05-04 김용원 물탱크 내의 스팀집 슈퍼히터에 전력공급한 스팀공급으로 스팀터빈을 구동하는 것과 슈퍼히터로 스팀을 공급하는 스팀청소기에 발전기들을 설치하는 것과 공기터빈의 흡입구들의 공기필터들 설치와 펠티에소자를 이용한 냉온 공기배출과 얼음제조기 시스템
KR20220056835A (ko) 2022-04-18 2022-05-06 김용원 공기추진기(공기펌프와 여러 공기터빈들)들을 장착한 수상 자전거
KR20220076421A (ko) 2022-05-11 2022-06-08 김용원 공기추진기(공기펌프와 공기터빈들)들을 장착한 페달자전차
KR20220080053A (ko) 2022-05-27 2022-06-14 김용원 다중 에어 레이어 튜브보트
KR20240124226A (ko) * 2023-02-08 2024-08-16 주식회사 인벤테라 체내 구조물 사이에서 응집없이 압축가능한 다당류 가교 콜로이드 입자 및 이의 생체내 주입용 개질제로서의 용도

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713249A (en) * 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
SE8204244L (sv) * 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
US4963526A (en) * 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
EP0247077A1 (en) 1985-10-22 1987-12-02 ROBINSON, Eric Process for cell immobilisation
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
USRE37950E1 (en) 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
US5618531A (en) * 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5840290A (en) * 1996-05-30 1998-11-24 University Of Florida Research Foundation Injectable bio-active glass in a dextran suspension
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
ATE322890T1 (de) * 1996-11-19 2006-04-15 Octoplus B V Verfahren zur herstellung eines systems mit gesteuerter freisetzung
US6395302B1 (en) * 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
EP0842657A1 (en) 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
FR2764514B1 (fr) * 1997-06-13 1999-09-03 Biopharmex Holding Sa Implant injectable en sous-cutane ou intradermique a bioresorbabilite controlee pour la chirurgie reparatrice ou plastique et la dermatologie esthetique
WO1999002107A1 (en) 1997-07-10 1999-01-21 Us Biomaterials Corporation Moldable bioactive compositions
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US20020054914A1 (en) 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
US7776359B1 (en) * 1999-02-19 2010-08-17 Universiteit Utrecht Stereocomplex hydrogels
FR2794649B1 (fr) * 1999-06-11 2003-04-11 Solutions Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance, son procede de preparation et ses applications
CA2385887A1 (en) * 1999-09-27 2001-04-05 John C. Lee Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
EP1184032A1 (en) * 2000-08-31 2002-03-06 OctoPlus B.V. Dextran hydrogels
FR2814951B1 (fr) * 2000-10-06 2003-01-17 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs hydrophiles (insuline) et leur mode de preparation
CA2429100A1 (en) * 2000-11-16 2002-05-23 Jagotec Ag Parenterally administrable microparticles
WO2002067995A1 (en) * 2001-02-26 2002-09-06 Council Of Scientific And Industrial Research Carrier systems comprising vitamin b12 - biodegradable micro particulate conju gates for peroral delivery of drugs, peptides/proteins and vaccines
NZ519403A (en) * 2001-06-21 2005-03-24 Pfizer Prod Inc Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels
JP2006519252A (ja) * 2003-03-04 2006-08-24 ザ・テクノロジー・デヴェロップメント・カンパニー・リミテッド 薬物送達系および細胞療法
SE529040C2 (sv) * 2006-01-18 2007-04-17 Bows Pharmaceuticals Ag Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin

Also Published As

Publication number Publication date
CA2518136A1 (en) 2004-09-16
CA2518143A1 (en) 2004-09-16
EA200501421A1 (ru) 2006-04-28
BRPI0408100A (pt) 2006-03-01
AU2004216909A1 (en) 2004-09-16
US7544656B2 (en) 2009-06-09
MXPA05009493A (es) 2006-08-11
EA200501420A1 (ru) 2006-04-28
KR20060015472A (ko) 2006-02-17
TW200529869A (en) 2005-09-16
NO20054539L (no) 2005-12-01
EP1454631A1 (en) 2004-09-08
AU2004216908A1 (en) 2004-09-16
NO20054533L (no) 2005-12-02
AU2004216911A1 (en) 2004-09-16
KR20060015469A (ko) 2006-02-17
AR046485A1 (es) 2005-12-14
WO2004078198A1 (en) 2004-09-16
NO20054539D0 (no) 2005-10-03
ECSP056077A (es) 2006-08-30
ECSP056078A (es) 2006-08-30
JP2006519840A (ja) 2006-08-31
NO20054534D0 (no) 2005-10-03
US20040234616A1 (en) 2004-11-25
ATE485051T1 (de) 2010-11-15
ECSP056076A (es) 2006-08-30
NO20054533D0 (no) 2005-10-03
DE602004029630D1 (de) 2010-12-02
US20040234615A1 (en) 2004-11-25
EP1454630A1 (en) 2004-09-08
PT1454630E (pt) 2010-12-15
US20110097385A1 (en) 2011-04-28
BRPI0408105A (pt) 2006-03-01
US20100167985A1 (en) 2010-07-01
WO2004078196A1 (en) 2004-09-16
EA200501422A1 (ru) 2006-04-28
EP1603589A1 (en) 2005-12-14
NO20054534L (no) 2005-11-29
KR20060014027A (ko) 2006-02-14
US20100166855A1 (en) 2010-07-01
EP1454630B1 (en) 2010-10-20
JP2006519253A (ja) 2006-08-24
WO2004078197A1 (en) 2004-09-16
CA2518148A1 (en) 2004-09-16
JP2006519252A (ja) 2006-08-24

Similar Documents

Publication Publication Date Title
BRPI0408097A (pt) composição de insulina oral e processos para a produção e para o uso da mesma
BRPI0312398B8 (pt) derivado de 1,3-difenilprop-2-en-1-ona substituído, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituído
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
AR047779A1 (es) Composiciones y metodos para tratar diabetes
MA29860B1 (fr) Modulateurs du metabolisme et le traitement de troubles s'y rapportant
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
BR0315720A (pt) Composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìmefero, formulação farmacêutica, combinação, uso de um composto, processo para a preparação de um composto, e, intermediário
BRPI0719486A2 (pt) "forma farmacêutica sólida oral desitegrante, não-efervescente, métodos para tratar uma mulher que necessite de um contraceptivo de emergência, pacote terapêutico para tratar uma mulher que necessite de contracepção de emergência e processo para a preparação de uma forma sólida de dosagem farmacêutica oral desintegrante, não-efervescente"
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BRPI0912842A8 (pt) composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
WO2008061226A3 (en) Sustained-release formulations of topiramate
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
BR0212929A (pt) Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, utilização de compostos, e método para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, disfunção renal, distúrbios alimentares e obesidade
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
BRPI0517701A (pt) uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BRPI0415713A (pt) mio-inositol hexafosfato para uso tópico
BR0014142A (pt) Composição de vacina e método de empregar a mesma
BR0016135A (pt) Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
BR9913746E8 (pt) derivado de piridínio, processo para a preparação do composto, uso do composto, composição farmacêutica para o tratamento de complicações diabéticas e doenças relacionadas ao envelhecimento, processo para preparação de uma formulação parenteral,processo para o tratamento de um paciente diabético pela ruptura de um age pré-formado dentro do paciente,e,processo de prevenção ou de tratamento de doenças causadas por diabetes e por complicações relacionadas com o envelhecimento.
AR053928A1 (es) Metodos reactivos para el tratamiento de trastornos inflamatorios
BR0308229A (pt) Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio
BRPI0406634A (pt) Uso de um anagrelìdeo, anagrelìdeo na forma de base, ou um sal farmaceuticamente aceitável do anagrelìdeo, composição farmacêutica não-oral, e dispositivo médido para administração transdérmica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 8A ANUIDADES.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A E 11A ANUIDADES.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.